PDCD1 and neoplasm: Mice were then given 4 doses of either IgG or anti-PD-1 treatment (secondary therapy) over the following 10-day period (days 11, 14, 17, and 20 post-IRE), and tumor growth was tracked >30 additional days (Fig. 9c).